1. Home
  2. GPRO vs SGMT Comparison

GPRO vs SGMT Comparison

Compare GPRO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$0.76

Market Cap

154.6M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.25

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRO
SGMT
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
154.6M
169.4M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
GPRO
SGMT
Price
$0.76
$5.25
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.38
AVG Volume (30 Days)
4.3M
334.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
79.08
N/A
EPS
N/A
N/A
Revenue
$651,542,000.00
$2,000,000.00
Revenue This Year
$23.14
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$1.73
52 Week High
$3.05
$11.41

Technical Indicators

Market Signals
Indicator
GPRO
SGMT
Relative Strength Index (RSI) 49.61 52.43
Support Level $0.69 $4.97
Resistance Level $1.02 $6.72
Average True Range (ATR) 0.06 0.31
MACD 0.02 0.06
Stochastic Oscillator 88.96 91.11

Price Performance

Historical Comparison
GPRO
SGMT

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: